Connect with us
The biotech industry thrived during the pandemic, fueled by vaccine demand, but post-2022 saw capital declines. In 2024, capital increases reached €999 million, led by Qiagen...
German biotech financing surged 78% in 2024, totalling €1.92 billion, driven by venture capital (€898 million), public market funding (€999 million), and an IPO. Notable deals...
Global markets saw mixed performances: DAX fell 0.6% to 19,909 points, pressured by BASF, BMW, and Bayer. MDAX and TecDAX also dropped. Hang Seng gained 0.7%,...
In 2024, Spanish pharma focused on stabilizing finances rather than expanding, with six major players seeing an 18% profit drop compared to 2023. While Faes Farma...
Zerintia HealthTech, a Spanish digital health firm, expands into Saudi Arabia and the UAE with its 4RemoteHealth platform, enabling real-time remote collaboration in complex medical settings....
Grifols faced a turbulent 2024 with leadership changes, legal battles, and debt refinancing. Accusations by Gotham City Research and a rejected takeover bid from Brookfield added...
Novartis plans to sell Morphosys' business, acquired for €2.7 billion in 2023, affecting 330 employees as it closes two factories by 2025. Initially aimed at boosting...
Novo Nordisk completed the €10.66 billion acquisition of Catalent, including three production plants to scale up Wegovy production. Despite rivals' opposition, the deal secures Novo’s market...
Roche's CE Mark-approved cobas Mass Spec offers automated, standardized mass spectrometry for over 60 tests, improving care for breast cancer and hormonal therapy patients. It aids...
Ozempic, manufactured by Novo Nordisk, gains EMA approval for chronic kidney disease, reducing disease progression by 24%, per the Flow trial. With 40% of type 2...
 |
|
 |  |
 |
|